98/100
High Financial Strength
40/100
Mid Valuation
38/100
Technically Neutral
Strength
10
Weakness
3
Opportunity
2
Threats
0
Market Cap (Cr)
PE Ratio
Price to Book Ratio
RSI
Net Profit Margin
Ipca Laboratories reported a standalone quarterly net loss of Rs. 65.05 crore for March 2025, a 200.45% decline from Rs. 64.76 crore in March 2024. Net sales rose 8.46% to Rs. 1,638.44 crore, while EBITDA increased 23.63% to Rs. 380.08 crore. Shares closed at 1,369.30 on NSE, delivering -10.14% returns over six months and 16.37% over 12 months.
Ipca Laboratories's stock fell 2.08% to Rs 1,386.30, marking it as a loser in the NIFTY MIDCAP 150 index. The company showed consistent revenue growth from Rs 4,648.71 Cr in 2020 to Rs 7,705.04 Cr in 2024. Its latest quarterly results for March 2025 reported Rs 2,246.69 Cr in revenue, Rs 65.78 Cr in net profit, and an EPS of Rs 2.67.
IPCA Laboratories reported a 14% year-on-year rise in net profit to ₹68 crore for the March quarter, with revenue increasing 11% to ₹2,247 crore. EBITDA surged 33% to ₹429 crore, and margins expanded to 19.09%. The board recommended a ₹2 per share dividend. Shares fell 0.84% post-earnings, down 12% in 2025.
Shares of Indian pharma companies, including Aurobindo Pharma, IPCA Laboratories, and Lupin, fell up to 5% after US President Donald Trump announced upcoming tariffs on the sector. Aurobindo Pharma dropped 6%, while others declined 4-5%. The declines followed Trump's remarks on imposing "unseen before" pharmaceutical tariffs, reversing gains from a temporary exemption announced earlier.
Indian pharmaceutical shares rose after the US exempted the sector from new trade tariffs, boosting the Nifty Pharma index by 2.3%. Companies like IPCA Laboratories, Lupin, Sun Pharma, and Cipla saw gains of 3-4%. Analysts expect further growth, with Motilal Oswal favoring Sun Pharma and BNP Paribas highlighting minimal impact from potential future tariffs.
Indian pharmaceutical stocks dropped up to 3% on BSE amid fears of U.S. tariffs announced by President Donald Trump, impacting companies like 📌Aurobindo Pharmaceuticals, 📌Ipca Laboratories, and 📌Sun Pharmaceuticals. Potential U.S. tariffs could cost India $6-31 billion in exports. Despite this, experts remain optimistic about the sector's long-term growth driven by strong domestic demand.
Pharma major IPCA Laboratories Ltd. reported its December quarter earnings on Thursday, February 13, where its net profit surged 38% year-on-year to ₹248 crore. The same was ₹180 crore in the same quarter of last year. The pharma company's revenue rose 9.4% year-on-year to ₹2,245.4 crore, compared to ₹2,053 crore in the year-ago quarter.
After a period of sluggish corporate earnings growth in 1HFY25, Indian market is poised for a recovery in 3QFY25. Key sectors like BFSI, capital goods, technology, healthcare, and real estate will lead the growth. IPCA Labs and Coforge are expected to perform well. Overall corporate earnings are expected to grow, although the metals and cement sectors may face challenges.
The Indian stock market benchmark Nifty 50 is expected to end 2024 with 9% gains despite current volatility, with experts recommending six stocks for short-term gains: 📌State Bank of India, 📌Aditya Birla Sun Life AMC, 📌Caplin Point Laboratories, 📌IPCA Laboratories, 📌PB Fintech, and 📌Blue Star, with potential returns ranging from 7% to 18% in the next 3-4 weeks.
Traders are focusing on select stocks with strong rollovers to the January series, indicating bullish momentum. Top picks include 📌IPCA Labs, 📌United Spirits, 📌Sun Pharmaceutical, 📌Interglobe Aviation, and 📌ICICI Bank, with price targets ranging from Rs 1,730 to Rs 4,820, while 📌Hindalco Industries is seen as a bearish bet with a target of Rs 595-580.
Motilal Oswal recommends buying 📌KEI Industries and 📌Ipca Laboratories due to strong growth projections and strategic expansion. KEI shows 19% upside potential, with robust retail growth and innovations. Ipca targets a 21% increase with its US market expansion. Goldman Sachs maintains a "Buy" on 📌UltraTech Cement, predicting a 9% rise, driven by demand growth and cost strategies.
Recommendations for traders who have a short-term trading horizon- 💰IPCA Laboratories: Buy| Target Rs 1790| Stop Loss Rs 1568 💰Petronet LNG: Buy| Target Rs 367| Stop Loss Rs 330 💰Radico: Buy| Target Rs 2880| Stop Loss Rs 2420 💰Sun Pharma: Buy| Target Rs 1950| Stop Loss Rs 1830 💰NTPC: Buy| Target Rs 360| Stop Loss Rs 327 💰Container Corp: Buy| Target Rs 840| Stop Loss Rs 770
📌IPCALAB has broken out from an "Adam & Eve" pattern, signaling that buyers have overtaken the sellers. Buy IPCA Laboratories at Rs 1,632.6, Target Price: Rs 1,715, Stop Loss: Rs 1,594. 📌On the daily timeframe, MANGLMCEM surged by 7.54%, forming a bullish candle and closing at a one-month high. Buy Mangalam Cement at Rs 981.10, Target Price: Rs 1,050, Stop Loss: Rs 956.
India's pharma industry is expected to grow 9-11% in FY2026, driven by price hikes, new launches, and export demand. Motilal Oswal Wealth Management recommends a basket of five stocks: 💰Mankind Pharma, 💰Max Healthcare, 💰Lupin, 💰IPCA Labs, and 💰Piramal Pharma, with potential upsides ranging from 10-23%.
Honeywell Automation, Kaynes Technology, Ipca Labs, and Dr Reddy's defied the weak market sentiment after gaining between 3 percent - 5 percent on December 19.Sensex was down 1.17 percent while the Nifty 50 was down 1 percent at 1.28 pm. The positivity around Ipca Labs and Dr Reddy's was more to do with the overall positivity around pharma after Trump came to power.
Reported Consolidated quarterly numbers for Ipca Laboratories are: Net Sales at Rs 2,354.90 crore in September 2024 up 15.78% from Rs. 2,033.96 crore in September 2023. Quarterly Net Profit at Rs. 229.48 crore in September 2024 up 58.2% from Rs. 145.06 crore in September 2023. EBITDA stands at Rs. 467.74 crore in September 2024 up 29.99% from Rs. 359.82 crore in September 2023.
InCred Equities has reduced its Nifty target by 3% from current levels and upgraded its stance on the pharma sector to "overweight," driven by positive revisions in stocks such as 📌Cipla, 📌Ipca Laboratories, and 📌Alkem Laboratories. It revised its Nifty target to 25,327 points, citing a delay in RBI's anticipated repo rate cuts and high expectations surrounding second-half earnings growth.
Technical analysts expect the Nifty to extend Friday’s upward momentum, potentially reaching the 24,500 zone. However, a break below 23,500 could trigger selling pressure, dragging the index toward 23,300–23,000 levels. Stocks such as 📌L&T Tech, 📌Bharti Airtel, 📌HCL Tech, 📌Infosys, 📌Tech Mahindra, 📌Ipca Labs, 📌Divis Labs, 📌DLF, and 📌National Aluminium show bullish chart pattern.
Order Received Under Central Goods And Service Tax Act 2017
The Company has enclosed herewith order received under Central Goods and Service Tax Act 2017
Closure of Trading Window
Closure of Trading Window
Change In The Name Of Statutory Audit Firm
Change in the name of Statutory Audit Firm
Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Dr. Nagaji Ambabhai Vekariya as President - CRD
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analysts Group Meeting on 17.06.2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
The Company has enclosing herewith copy of newspaper publication issued to shareholders in respect of transfer of equity shares to IEPF.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for the Conference Call held on 30.05.2025
Compliances-Reg.24(A)-Annual Secretarial Compliance
Secretarial Compliance Report for FY25
Board Meeting Outcome for Standalone And Consolidated Audited Financial Results For Q4FY25
Standalone and Consolidated Audited Financial Results for Q4FY25
Announcement under Regulation 30 (LODR)-Dividend Updates
Recommendation of Final Dividend for FY25
Standalone And Consolidated Audited Financial Results For Q4FY25
Standalone and Consolidated Audited Financial Results for Q4FY25
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Amendment to Memorandum of Association
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call on 30.05.2025 for Q4FY25
Board Meeting Intimation for Standalone & Consolidated Audited Financial Results For The 4Th Quarter And FY25 And Recommendation Of Final Dividend For FY 24-25
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve Standalone & Consolidated Audited Financial Results for the 4th Quarter and FY25 and recommendation of final... More>
General Updates - Unichem Laboratories Ltd. Ireland
Transfer of 100% paid-up equity share capital of Unichem Laboratories Ltd. Ireland
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
The Company has enclosed herewith certificate received from RTA under Reg74(5) SEBI DP Regulations 2018 for the quarter ended 31.03.2025
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Reg 30 (LODR) - Acquisition
Slump Sale Of Manufacturing Unit And Acquisition
Slump Sale of Manufacturing Unit and Acquisition
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting - 28.03.2025
Closure of Trading Window
Closure of Trading Window
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Conference Call held on 14.08.2024 for Q1FY25 Results
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Voting Results & Scrutinizer Report of the 74th Annual General Meeting held on 13th August 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for the Investors Conference Call held on 14.08.2024
Approval Of Shareholders For Re-Appointment / Appointment Of Directors
Approval of shareholders for re-appointment / appointment of Directors
Standalone And Consolidated Unaudited Financial Results For Q1FY25
Standalone and Consolidated Unaudited Financial Results for Q1FY25
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY25
Standalone and Consolidated Unaudited Financial Results for Q1FY25
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 74th Annual General Meeting held on 13.08.2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call to discuss Q1FY25 Results
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Kotak Mahindra Mutual Fund
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Media Release for launch of patented novel drug branded Diulcus in the Indian market for treatment of Diabetic Foot Ulcer (DFU)
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results Of The Company
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Standalone and Consolidated unaudited financial results of the Company for the 1st quarter ended 30th June... More>
74Th Annual General Meeting Of The Company To Be Held On Tuesday 13Th August 2024 At 3.30 P.M.
74th Annual General Meeting of the Company to be held on Tuesday 13th August 2024 at 3.30 p.m.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Book Closure For Annual General Meeting And Members Entitlement Of Dividend
Book Closure for Annual General Meeting and Members entitlement of dividend
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Reporting (BRSR)
Reg. 34 (1) Annual Report.
Annual Report 2023-24
Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating for Companys commercial paper working capital limits and long-term loan
Superannuation Of Dr. Goutam Muhuri President - R&D (Formulations) From The Services Of The Company.
Superannuation of Dr. Goutam Muhuri President - R&D (Formulations) from the services of the Company
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Reg 74(5) of DP Regulations 2018 enclosed herewith Certificate received from RTA for the quarter ended 30.06.2024.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations
Judgement of Court of Justice of the EU
Closure of Trading Window
Closure of Trading Window
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Earnings Call
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link of the Conference Call held on 30.05.2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Dividend Updates
Board recommends final dividend
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31 2024
Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Vivek Shiralkar on Additional Director / Independent Director
Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May 2024
Outcome of Board Meeting held on 29th May 2024
Standalone And Consolidated Results For Q4 And FY24
Standalone and Consolidated Results for Q4 and FY24
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference call for Q4FY24 Audited Financial Results
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Board Meeting Intimation for Standalone And Consolidated Audited Financial Results For The 4Th Quart
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Standalone and Consolidated Audited Financial Results for the 4th quarter and financial year ended 31st March... More>
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligation
Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)Regulations 2015
Allotment Of Equity Shares Of Lyka Labs Ltd. On Conversion Of Warrants
Allotment of equity shares of Lyka Labs Ltd. on conversion of warrants
Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) R
Compliance Certificate under Regulation 7(3) of the SEBI (LODR) Regulations 2015.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018 for the Quarter ended 31 March 2024..
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Announcement under Regulation 30 (LODR)-Change in Directorate
Completion of second term of appointment of Mr. Anand T. Kusre as an Independent Director
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Voting Results & Scrutinizer Report
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Voting Results of the Postal Ballot alongwith Scrutinizer Report
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release w.r.t. Technology Transfer for development of an anti-cancer biosimilar for global market
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate.
Closure of Trading Window
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication in respect of dispatch of Postal Ballot Notice
Electronic Dispatch Of Postal Ballot Notice To The Shareholders Of The Company
Electronic Dispatch of Postal Ballot Notice to shareholders of the Company
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith Postal Ballot Notice seeking approval of the Members for the special resolutions set out in the attached Postal Ballot Notice
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of lost share certificate for which stop transfer has been marked by the Registrar
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
We are enclosing herewith transcript of our Conference Call which was held on Friday 16th February 2024 to discuss the Companys Q3 / Nine Months FY24 earnings and business update
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for Conference Call held on 15th February 2024.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of the Consolidated Unaudited Financial Results for the 3rd quarter and 9 months ended 31st December 2023
Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Dr. (Ms.) Swati Patankar as an Independent Director
Standalone And Consolidated Q3FY24 Results And Press Release
Standalone and Consolidated Q3FY24 Results and Press Release
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.02.2024
Outcome of Board Meeting held on 14.02.2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call to discuss the Companys Q3 FY24 earnings and business update to be held on Thursday 15th February 2024 at 15.30 hrs IST.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under regulation 39(3) of SEBI (LODR) Regulation 2015 for Loss of share certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The 3Rd Qua
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the 3rd quarter and nine months ended 31.12.2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2023
Ipca Laboratories reported a standalone quarterly net loss of Rs. 65.05 crore for March 2025, a 200.45% decline from Rs. 64.76 crore in March 2024. Net sales rose 8.46% to Rs. 1,638.44 crore, while EBITDA increased 23.63% to Rs. 380.08 crore. Shares closed at 1,369.30 on NSE, delivering -10.14% returns over six months and 16.37% over 12 months.
Ipca Laboratories's stock fell 2.08% to Rs 1,386.30, marking it as a loser in the NIFTY MIDCAP 150 index. The company showed consistent revenue growth from Rs 4,648.71 Cr in 2020 to Rs 7,705.04 Cr in 2024. Its latest quarterly results for March 2025 reported Rs 2,246.69 Cr in revenue, Rs 65.78 Cr in net profit, and an EPS of Rs 2.67.
IPCA Laboratories reported a 14% year-on-year rise in net profit to ₹68 crore for the March quarter, with revenue increasing 11% to ₹2,247 crore. EBITDA surged 33% to ₹429 crore, and margins expanded to 19.09%. The board recommended a ₹2 per share dividend. Shares fell 0.84% post-earnings, down 12% in 2025.
Shares of Indian pharma companies, including Aurobindo Pharma, IPCA Laboratories, and Lupin, fell up to 5% after US President Donald Trump announced upcoming tariffs on the sector. Aurobindo Pharma dropped 6%, while others declined 4-5%. The declines followed Trump's remarks on imposing "unseen before" pharmaceutical tariffs, reversing gains from a temporary exemption announced earlier.
Indian pharmaceutical shares rose after the US exempted the sector from new trade tariffs, boosting the Nifty Pharma index by 2.3%. Companies like IPCA Laboratories, Lupin, Sun Pharma, and Cipla saw gains of 3-4%. Analysts expect further growth, with Motilal Oswal favoring Sun Pharma and BNP Paribas highlighting minimal impact from potential future tariffs.
Indian pharmaceutical stocks dropped up to 3% on BSE amid fears of U.S. tariffs announced by President Donald Trump, impacting companies like 📌Aurobindo Pharmaceuticals, 📌Ipca Laboratories, and 📌Sun Pharmaceuticals. Potential U.S. tariffs could cost India $6-31 billion in exports. Despite this, experts remain optimistic about the sector's long-term growth driven by strong domestic demand.
Pharma major IPCA Laboratories Ltd. reported its December quarter earnings on Thursday, February 13, where its net profit surged 38% year-on-year to ₹248 crore. The same was ₹180 crore in the same quarter of last year. The pharma company's revenue rose 9.4% year-on-year to ₹2,245.4 crore, compared to ₹2,053 crore in the year-ago quarter.
After a period of sluggish corporate earnings growth in 1HFY25, Indian market is poised for a recovery in 3QFY25. Key sectors like BFSI, capital goods, technology, healthcare, and real estate will lead the growth. IPCA Labs and Coforge are expected to perform well. Overall corporate earnings are expected to grow, although the metals and cement sectors may face challenges.
The Indian stock market benchmark Nifty 50 is expected to end 2024 with 9% gains despite current volatility, with experts recommending six stocks for short-term gains: 📌State Bank of India, 📌Aditya Birla Sun Life AMC, 📌Caplin Point Laboratories, 📌IPCA Laboratories, 📌PB Fintech, and 📌Blue Star, with potential returns ranging from 7% to 18% in the next 3-4 weeks.
Traders are focusing on select stocks with strong rollovers to the January series, indicating bullish momentum. Top picks include 📌IPCA Labs, 📌United Spirits, 📌Sun Pharmaceutical, 📌Interglobe Aviation, and 📌ICICI Bank, with price targets ranging from Rs 1,730 to Rs 4,820, while 📌Hindalco Industries is seen as a bearish bet with a target of Rs 595-580.
Motilal Oswal recommends buying 📌KEI Industries and 📌Ipca Laboratories due to strong growth projections and strategic expansion. KEI shows 19% upside potential, with robust retail growth and innovations. Ipca targets a 21% increase with its US market expansion. Goldman Sachs maintains a "Buy" on 📌UltraTech Cement, predicting a 9% rise, driven by demand growth and cost strategies.
Recommendations for traders who have a short-term trading horizon- 💰IPCA Laboratories: Buy| Target Rs 1790| Stop Loss Rs 1568 💰Petronet LNG: Buy| Target Rs 367| Stop Loss Rs 330 💰Radico: Buy| Target Rs 2880| Stop Loss Rs 2420 💰Sun Pharma: Buy| Target Rs 1950| Stop Loss Rs 1830 💰NTPC: Buy| Target Rs 360| Stop Loss Rs 327 💰Container Corp: Buy| Target Rs 840| Stop Loss Rs 770
📌IPCALAB has broken out from an "Adam & Eve" pattern, signaling that buyers have overtaken the sellers. Buy IPCA Laboratories at Rs 1,632.6, Target Price: Rs 1,715, Stop Loss: Rs 1,594. 📌On the daily timeframe, MANGLMCEM surged by 7.54%, forming a bullish candle and closing at a one-month high. Buy Mangalam Cement at Rs 981.10, Target Price: Rs 1,050, Stop Loss: Rs 956.
India's pharma industry is expected to grow 9-11% in FY2026, driven by price hikes, new launches, and export demand. Motilal Oswal Wealth Management recommends a basket of five stocks: 💰Mankind Pharma, 💰Max Healthcare, 💰Lupin, 💰IPCA Labs, and 💰Piramal Pharma, with potential upsides ranging from 10-23%.
Honeywell Automation, Kaynes Technology, Ipca Labs, and Dr Reddy's defied the weak market sentiment after gaining between 3 percent - 5 percent on December 19.Sensex was down 1.17 percent while the Nifty 50 was down 1 percent at 1.28 pm. The positivity around Ipca Labs and Dr Reddy's was more to do with the overall positivity around pharma after Trump came to power.
Reported Consolidated quarterly numbers for Ipca Laboratories are: Net Sales at Rs 2,354.90 crore in September 2024 up 15.78% from Rs. 2,033.96 crore in September 2023. Quarterly Net Profit at Rs. 229.48 crore in September 2024 up 58.2% from Rs. 145.06 crore in September 2023. EBITDA stands at Rs. 467.74 crore in September 2024 up 29.99% from Rs. 359.82 crore in September 2023.
InCred Equities has reduced its Nifty target by 3% from current levels and upgraded its stance on the pharma sector to "overweight," driven by positive revisions in stocks such as 📌Cipla, 📌Ipca Laboratories, and 📌Alkem Laboratories. It revised its Nifty target to 25,327 points, citing a delay in RBI's anticipated repo rate cuts and high expectations surrounding second-half earnings growth.
Technical analysts expect the Nifty to extend Friday’s upward momentum, potentially reaching the 24,500 zone. However, a break below 23,500 could trigger selling pressure, dragging the index toward 23,300–23,000 levels. Stocks such as 📌L&T Tech, 📌Bharti Airtel, 📌HCL Tech, 📌Infosys, 📌Tech Mahindra, 📌Ipca Labs, 📌Divis Labs, 📌DLF, and 📌National Aluminium show bullish chart pattern.
Order Received Under Central Goods And Service Tax Act 2017
The Company has enclosed herewith order received under Central Goods and Service Tax Act 2017
Closure of Trading Window
Closure of Trading Window
Change In The Name Of Statutory Audit Firm
Change in the name of Statutory Audit Firm
Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Dr. Nagaji Ambabhai Vekariya as President - CRD
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analysts Group Meeting on 17.06.2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
The Company has enclosing herewith copy of newspaper publication issued to shareholders in respect of transfer of equity shares to IEPF.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for the Conference Call held on 30.05.2025
Compliances-Reg.24(A)-Annual Secretarial Compliance
Secretarial Compliance Report for FY25
Board Meeting Outcome for Standalone And Consolidated Audited Financial Results For Q4FY25
Standalone and Consolidated Audited Financial Results for Q4FY25
Announcement under Regulation 30 (LODR)-Dividend Updates
Recommendation of Final Dividend for FY25
Standalone And Consolidated Audited Financial Results For Q4FY25
Standalone and Consolidated Audited Financial Results for Q4FY25
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Amendment to Memorandum of Association
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call on 30.05.2025 for Q4FY25
Board Meeting Intimation for Standalone & Consolidated Audited Financial Results For The 4Th Quarter And FY25 And Recommendation Of Final Dividend For FY 24-25
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve Standalone & Consolidated Audited Financial Results for the 4th Quarter and FY25 and recommendation of final dividend for FY 24-25
General Updates - Unichem Laboratories Ltd. Ireland
Transfer of 100% paid-up equity share capital of Unichem Laboratories Ltd. Ireland
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
The Company has enclosed herewith certificate received from RTA under Reg74(5) SEBI DP Regulations 2018 for the quarter ended 31.03.2025
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Reg 30 (LODR) - Acquisition
Slump Sale Of Manufacturing Unit And Acquisition
Slump Sale of Manufacturing Unit and Acquisition
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting - 28.03.2025
Closure of Trading Window
Closure of Trading Window
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Conference Call held on 14.08.2024 for Q1FY25 Results
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Voting Results & Scrutinizer Report of the 74th Annual General Meeting held on 13th August 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for the Investors Conference Call held on 14.08.2024
Approval Of Shareholders For Re-Appointment / Appointment Of Directors
Approval of shareholders for re-appointment / appointment of Directors
Standalone And Consolidated Unaudited Financial Results For Q1FY25
Standalone and Consolidated Unaudited Financial Results for Q1FY25
Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY25
Standalone and Consolidated Unaudited Financial Results for Q1FY25
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 74th Annual General Meeting held on 13.08.2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call to discuss Q1FY25 Results
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Kotak Mahindra Mutual Fund
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Media Release for launch of patented novel drug branded Diulcus in the Indian market for treatment of Diabetic Foot Ulcer (DFU)
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results Of The Company
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Standalone and Consolidated unaudited financial results of the Company for the 1st quarter ended 30th June 2024 of the financial year 2024-25
74Th Annual General Meeting Of The Company To Be Held On Tuesday 13Th August 2024 At 3.30 P.M.
74th Annual General Meeting of the Company to be held on Tuesday 13th August 2024 at 3.30 p.m.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Book Closure For Annual General Meeting And Members Entitlement Of Dividend
Book Closure for Annual General Meeting and Members entitlement of dividend
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Reporting (BRSR)
Reg. 34 (1) Annual Report.
Annual Report 2023-24
Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating for Companys commercial paper working capital limits and long-term loan
Superannuation Of Dr. Goutam Muhuri President - R&D (Formulations) From The Services Of The Company.
Superannuation of Dr. Goutam Muhuri President - R&D (Formulations) from the services of the Company
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Reg 74(5) of DP Regulations 2018 enclosed herewith Certificate received from RTA for the quarter ended 30.06.2024.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations
Judgement of Court of Justice of the EU
Closure of Trading Window
Closure of Trading Window
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Earnings Call
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link of the Conference Call held on 30.05.2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Dividend Updates
Board recommends final dividend
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31 2024
Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Vivek Shiralkar on Additional Director / Independent Director
Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May 2024
Outcome of Board Meeting held on 29th May 2024
Standalone And Consolidated Results For Q4 And FY24
Standalone and Consolidated Results for Q4 and FY24
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference call for Q4FY24 Audited Financial Results
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Board Meeting Intimation for Standalone And Consolidated Audited Financial Results For The 4Th Quart
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Standalone and Consolidated Audited Financial Results for the 4th quarter and financial year ended 31st March 2024 and recommendation of final dividend for FY 23-24
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligation
Certificate under Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)Regulations 2015
Allotment Of Equity Shares Of Lyka Labs Ltd. On Conversion Of Warrants
Allotment of equity shares of Lyka Labs Ltd. on conversion of warrants
Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) R
Compliance Certificate under Regulation 7(3) of the SEBI (LODR) Regulations 2015.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018 for the Quarter ended 31 March 2024..
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate
Announcement under Regulation 30 (LODR)-Change in Directorate
Completion of second term of appointment of Mr. Anand T. Kusre as an Independent Director
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Voting Results & Scrutinizer Report
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Voting Results of the Postal Ballot alongwith Scrutinizer Report
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release w.r.t. Technology Transfer for development of an anti-cancer biosimilar for global market
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate.
Closure of Trading Window
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication in respect of dispatch of Postal Ballot Notice
Electronic Dispatch Of Postal Ballot Notice To The Shareholders Of The Company
Electronic Dispatch of Postal Ballot Notice to shareholders of the Company
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith Postal Ballot Notice seeking approval of the Members for the special resolutions set out in the attached Postal Ballot Notice
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of lost share certificate for which stop transfer has been marked by the Registrar
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
We are enclosing herewith transcript of our Conference Call which was held on Friday 16th February 2024 to discuss the Companys Q3 / Nine Months FY24 earnings and business update
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link for Conference Call held on 15th February 2024.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of the Consolidated Unaudited Financial Results for the 3rd quarter and 9 months ended 31st December 2023
Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Dr. (Ms.) Swati Patankar as an Independent Director
Standalone And Consolidated Q3FY24 Results And Press Release
Standalone and Consolidated Q3FY24 Results and Press Release
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.02.2024
Outcome of Board Meeting held on 14.02.2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Conference Call to discuss the Companys Q3 FY24 earnings and business update to be held on Thursday 15th February 2024 at 15.30 hrs IST.
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under regulation 39(3) of SEBI (LODR) Regulation 2015 for Loss of share certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The 3Rd Qua
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the 3rd quarter and nine months ended 31.12.2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2023
OTP sent to your mobile number/email. Please enter it below to verify.
